The HCFC1R1 Knockout KYSE-30 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the human KYSE-30 esophageal squamous cell carcinoma line, engineered for targeted disruption of the HCFC1R1 gene. This product provides a heterogeneous pool of edited cells, offering a robust loss-of-function model to investigate HCFC1R1-dependent regulatory mechanisms without the need for single-cell cloning. The polyclonal format captures the diversity of CRISPR-induced gene disruptions, enabling population-level functional studies in a well-characterized cancer model.
The parental KYSE-30 cell line was established from a well-differentiated esophageal squamous cell carcinoma resected from a 64-year-old male patient. KYSE-30 cells retain key characteristics of well-differentiated ESCC, including epithelial morphology and defined squamous differentiation markers, making them a physiologically relevant host for studying gene function in esophageal carcinogenesis. Their well-documented growth properties and responsiveness to standard culture conditions facilitate reproducible experimental manipulation, particularly in cell cycle and proliferation analyses.
HCFC1R1 functions as a critical negative regulator of the HCFC1 transcriptional coactivator, a central component of the E2F-dependent gene expression program governing G1/S cell cycle transition. Under normal conditions, HCFC1R1 interacts with SIN3A and HDAC-containing repressor complexes to limit HCFC1 activity, thereby restraining transcription of E2F target genes such as CCNE (cyclin E) and CCNB1 (cyclin B). HCFC1R1 expression and activity are modulated by upstream E2F transcription factors and mitogen-activated signaling cascades, placing it at a key regulatory node that integrates proliferative signals with cell cycle machinery. Disruption of HCFC1R1 lifts this transcriptional repression, resulting in enhanced HCFC1 coactivator function and increased E2F-dependent gene expression, which accelerates G1/S progression.
In the context of KYSE-30 esophageal squamous cell carcinoma cells, HCFC1R1 knockout amplifies oncogenic potential driven by dysregulated E2F activity, a hallmark of many cancers. This model enables dissection of how loss of HCFC1R1-mediated restraint on HCFC1/E2F contributes to uncontrolled proliferation, checkpoint resistance, and altered differentiation. Since ESCC often exhibits pRb pathway inactivation and E2F hyperactivation, these cells are a valuable tool for exploring therapeutic strategies targeting cell cycle control.
Researchers can employ this knockout model in a broad range of functional and mechanistic studies, including western blotting and RT-qPCR for expression analysis, MTS/MTT proliferation assays, flow cytometric cell cycle profiling, apoptosis detection, chromatin immunoprecipitation (ChIP) to assess E2F promoter occupancy, and co-immunoprecipitation to probe HCFC1-complex dynamics. Specific applications include tumor suppressor gene characterization, drug resistance screening, and validation of cell cycle targets in esophageal cancer. For detailed protocols, technical support, or custom applications, please contact Ascent Research.
